ADVANCE ONLINE PUBLICATION

RESEARCH HIGHLIGHTS

A SNIPpet of safety: a Goldilocks approach in CAR-T therapy

Mehdi Benzaoui^1,2 , Naomi Taylor^1,2,* , Nirali N. Shah^1,*

¹Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA
²Institut de Génétique Moléculaire de Montpellier, Univ Montpellier, CNRS, Montpellier, France
* Correspondence: Naomi Taylor(taylorn4@mail.nih.gov)Nirali N. Shah(nirali.shah@mail.nih.gov)

Despite the remarkable efficacy of chimeric antigen receptor (CAR) T-cells in B-cell malignancies, their full potential in solid tumors has not yet been achieved. In a recent publication in Cell , Labanieh et al. developed a druggable CAR T-cell construct that allows optimal fine-tuning of CAR T-cells to achieve maximal efficacy and reduce toxicity.

https://doi.org/10.1038/s41422-022-00682-2

FULL TEXT | PDF

Browse 315